Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

• Status: Completed
• Trial end date: 2018-09-30
• Target enrollment: 0
• Participant gender: All

Summary

This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Genvoya for four weeks

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
• Collaborator: Gilead Sciences
• Treatments: Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination

Criteria

Inclusion Criteria:

• an age above 18 years

• consultation within 48 hours following a risk of HIV transmission (blood or sexual contact)

• indication for HIV post-exposure prophylaxis (according to French guidelines)

• person able to understand the nature of the study

• person who signed his consent form to participate in the study

Exclusion Criteria:

• person exposed to HIV risk from person infected by HIV, whose therapeutic history justifies the prescription of another combination of antiretroviral drugs

• contraindications to the prescription of Genvoy

• other medical contraindications

• person infected by hepatitis B virus

• pregnant or lactating woman